Literature DB >> 1125561

Which techniques should be used to screen blood donations for hepatitis B surface antigen?

J Wallace, A Barr, G R Milne.   

Abstract

Preservation of all donor sera already tested for Hepatitis B surface antigen (HBsAg) by counterimmunoelectrophoresis (C.I.E.P.) allowed C.I.E.P., reversed passive haemagglutination (R.P.H.A.), and radioimmunoassay (R.I.A.) to be evaluated as screening techniques. Out of 165 811 donors tested for the first time 207 were found by C.I.E.P. to be positive for HBsAf-a prevalence of 0-12%. At the next donation 10 of those apparently negative on first screening were HBsAg positive by C.I.E.P., and nine of these were shown by retesting with R.P.H.A. and R.I.A. to have been positive at the earlier donation. These nine false negatives caused four cases of transfusion-transmitted HBsAg-positive hepatitis. On comparative screening of 22 239 donations C.I.E.P. detected 27 sera positive for HBsAg, R.P.H.A. 39, and R.I.A. 41. Thus R.I.A. increased the detection rate by more than half over C.I.E.P. From these 14 further false-negative donations by C.I.E.P. six cases-one fatal-of HBsAg-positive hepatitis occurred. The number of false positive reactions when using R.P.H.A. or R.I.A. for screening was less than 1%. As many as 700 donations in one day have been tested by R.P.H.A. or R.I.A. R.P.H.A. is faster and less expensive than R.I.A., but R.I.A. is more objective. Either R.P.H.A. or R.I.A. should replace C.I.E.P. as the routine method of screening donor sera for HBsAg.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1125561      PMCID: PMC1681838          DOI: 10.1136/bmj.2.5968.412

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  9 in total

Review 1.  Hepatitis in transfusion services.

Authors: 
Journal:  Br Med Bull       Date:  1972-05       Impact factor: 4.291

2.  Letter: Prevention of post-transfusion hepatitis.

Authors:  A Arndt-Hanser; R Anantharkrishnan; K Ewe; K H Holtermuller; A Kohler; H Fiedler; G Maass; V Reinicke; E Dybkjaer; G Rossi; C Vermylen
Journal:  Lancet       Date:  1974-08-10       Impact factor: 79.321

3.  Long-incubation post-transfusion hepatitis without serological evidence of exposure to hepatitis-B virus.

Authors:  A M Prince; B Brotman; G F Grady; W J Kuhns; C Hazzi; R W Levine; S J Millian
Journal:  Lancet       Date:  1974-08-03       Impact factor: 79.321

4.  Evaluation of a new haemagglutination technique for the demonstration of hepatitis-B antigen.

Authors:  H W Reesink; W J Duimel; H G Brummelhuis
Journal:  Lancet       Date:  1973-12-15       Impact factor: 79.321

5.  Australia antigen in blood donors.

Authors:  J Wallace
Journal:  Lancet       Date:  1973-05-05       Impact factor: 79.321

6.  Specificity of the direct solid-phase radioimmunoassay for detection of hepatitis-B antigen.

Authors:  A M Prince; B Brotman; D Jass; H Ikram
Journal:  Lancet       Date:  1973-06-16       Impact factor: 79.321

7.  Kinetic studies on the direct solid phase radioimmunoassay for hepatitis B antigen.

Authors:  A M Prince; D Jass
Journal:  Vox Sang       Date:  1974-03       Impact factor: 2.144

8.  Prevalence of hepatitis B virus antigen as revealed by direct radioimmune assay with 125 I-antibody.

Authors:  C M Ling; L R Overby
Journal:  J Immunol       Date:  1972-10       Impact factor: 5.422

9.  Total screening of blood donations for Australia (hepatitis associated) antigen and its antibody.

Authors:  J Wallace; G R Milne; A Barr
Journal:  Br Med J       Date:  1972-03-11
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.